Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia
We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies torestore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH)and to enhance the macrophage-specific reverse cholesterol transport pathway in mice. Analyses ofmacrophage-derived cholesterol distribution of plasma from FH patients revealed that low-density li-poprotein (LDL) particles contained less, and high-density lipoprotein particles contained more radio-labeled cholesterol after treatment with either PCSK9 inhibitor. PCSK9 antibodies facilitated thetransfer of macrophage-derived cholesterol and LDL-derived cholesterol to feces exclusively inheterozygous LDL receptor-deficient mice expressing human APOB100. PCSK9 inhibitors act aspositive regulators of the macrophage-specific reverse cholesterol transport pathway in individuals withheterozygous FH.
Project:
Instituto de Salud Carlos III PI2100140
,
Instituto de Salud Carlos III PI2101523
,
Instituto de Salud Carlos III PI2300232
,
Instituto de Salud Carlos III JR22/00003
,
Agencia Estatal de Investigación RTI2018-098113-B-I00
,
Fundació la Marató de TV3 12/C/2015
,
Agencia Estatal de Investigación RYC-201722879
,
Ministerio de Ciencia FPU20/07440